Early detection of ovarian cancer is crucial, with a 5-year survival rate exceeding 90%. Once this early window has been missed, the 5-year survival rate precipitously drops below 50%.
Stanford researchers have developed high-titer bacteriophage and annexin V formulations for rapid, more effective phage therapy against bacterial infection.